Maraviroc intensification in patients with suppressed HIV viremia has limited effects on CD4+ T cell recovery and gene expression

Addition of the CCR5 inhibitor Maraviroc (MVC) to ongoing antiretroviral therapy increases CD4+ T cell counts in some virologically suppressed patients with suboptimal CD4+ T cell recovery. To understand the mechanisms by which MVC elicits increases in CD4+ T cell counts, the present study was under...

詳細記述

保存先:
書誌詳細
主要な著者: Beliakova-Bethell, Nadejda, Jain, Sonia, Woelk, Christopher H., Witt, Mallory D., Sun, Xiaoying, Lada, Steven M., Spina, Celsa A., Goicoechea, Miguel, Rought, Steffney E., Haubrich, Richard, Dubé, Michael P.
フォーマット: Artigo
言語:Inglês
出版事項: 2014
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4116489/
https://ncbi.nlm.nih.gov/pubmed/24769244
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.antiviral.2014.04.005
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料